Loading data for IMMX — first visit, this takes a few seconds.

Alerta

Immix Biopharma Inc. (IMMX)

NasdaqCM: IMMX · Precio en tiempo real · USD

13.19

+1.38 (11.69%)

Al cierre: Aug 19, 2026, 8:00 PM

13.20

+0.08%

Fuera de horario: 7:45 PM

11.69% (1D)

No hay datos disponibles

Precio de compra	9.36
Capitalización de mercado	939M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-39.92M
Beta	0.11
EPS (TTM)	-0.98
Ratio PER (TTM)	n/a
Adelante PE	-14.59
P/B (TTM)	4.12
P/S (TTM)	n/a
Earnings Date	n/a

Precio de venta	15.36
Volumen	1,958,312
Volumen medio (20D)	1,912,380
Abierto	11.99
Anterior Cerrar	11.81
Rango del día	11.99 - 13.19
Rango de 52 semanas	1.94 - 13.19
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de IMMX

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California....

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Dec 16, 2021

Empleados 21

Bolsa de Valores NasdaqCM

Símbolo bursátil IMMX

Sitio web https://www.immixbio.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Immix Biopharma fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -29.44M, un aumento de 36.21%.

Estados financieros

Sorpresa de resultados

Immix Biopharma ha publicado sus resultados trimestrales en Aug 7, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.18 falla las estimaciones por 0.00, con 18.18% Crecimiento interanual.

Noticias

4 semanas hace · Investor's Business Daily

Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run

One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.

2 meses hace · Zacks

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

2 meses hace · Simply Wall St.

Exploring 3 High Growth Tech Stocks in the US Market

Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying...

2 meses hace · Zacks

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

3 meses hace · Simply Wall St.

3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%

Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing envir...

Página 1 de 2

Immix Biopharma Inc. (IMMX)